模拟人体器官服务科研新范式，广州创芯国际获亿元B轮融资

Core Insights - Chuangxin International Biotechnology (Guangzhou) Co., Ltd. has completed nearly 100 million RMB in Series B financing, led by Yueke Fund and Zhongshan Haochuang Fund, to accelerate the development and global commercialization of organoid technology [2][3] - Organoids, derived from stem cells and cultivated in 3D, closely mimic the genetic characteristics and structure of the source tissue, making them crucial tools in precision medicine and innovative drug development [2] - The global life sciences research paradigm is shifting from animal models to human cell models, with the FDA planning to phase out animal testing by April 2025, recommending the use of organoids [2] Company Overview - Chuangxin International is a full-chain innovative enterprise in the organoid field, focusing on precision medicine, new drug development, and intelligent manufacturing [2] - The company has established a comprehensive ecosystem covering the entire lifecycle of organoids, aiming to drive the industry towards intelligence, standardization, and industrialization [2] Investment Perspective - Yueke Fund recognizes Chuangxin International's leading organoid technology and its significant application value in precision medicine and new drug development, aligning with its investment philosophy [3] - The investment from Tohoku East, which focuses on early to mid-stage tech enterprises, is seen as a strategic move to enhance the development of the biomedical industry cluster in the Guangdong-Hong Kong-Macao Greater Bay Area [3] Future Plans - Chuangxin International plans to leverage this financing round to build a technology ecosystem covering the entire lifecycle of organoids, focusing on core technology research and product innovation [3] - The company aims to create a product matrix in key areas such as organoid intelligent devices, chips, and data intelligence systems, striving to become a global leader in the organoid industry [3]